Overview

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is a single and multiple ascending dose study in healthy male and female (of non-child bearing potential) Japanese and White volunteers, to assess the safety, tolerability, and blood and urine drug levels of FosD. FosD is being developed for the treatment of rheumatoid arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca